Efficient and nontoxic adenoviral purging method for autologous transplantation in breast cancer patients

• Published in: Cancer research (Chicago, Ill.) Ill.), 2002-09, Vol.62 (17), p.5013-5018
• Main Authors: LILLO, Rosa, RAMIREZ, Manuel, VICARIO, José Luis, BUEREN, Juan Antonio, GARCIA-SANCHEZ, Félix, ALVAREZ, Angela, SANTOS, Silvia, GARCIA-CASTRO, Javier, FERNANDEZ DE VELASCO, Jaime, AVILES, Maria José, GOMEZ-PINEDA, Alfonso, DIEZ, José Luis, BALAS, Antonio
• Format: Article
• Language: English
• Subjects: Adenoviridae - genetics; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Animals; Applied cell therapy and gene therapy; Biological and medical sciences; Bone Marrow Purging - methods; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Cytosine Deaminase; Female; Flucytosine - pharmacokinetics; Genetic Therapy - methods; Gynecology. Andrology. Obstetrics; Hematopoietic Stem Cell Transplantation - methods; Humans; Male; Mammary gland diseases; Medical sciences; Mice; Mice, Inbred NOD; Mice, SCID; Nucleoside Deaminases - genetics; Nucleoside Deaminases - metabolism; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Tumor Cells, Cultured; Tumors
• ISSN: 0008-5472; 1538-7445

Tumor cell contamination of clinical grafts is a major concern in autologous hematopoietic stem cell transplantation because these contaminating cells can contribute to relapse. In the present work, we use a suicide gene therapy approach that successfully accomplishes the two main goals of any purging strategy: highly efficient elimination of contaminating tumor cells and preservation of the engraftment capability of the hematopoietic progenitor cells. Human CD34(+) cells spiked with breast cancer cells were infected with an adenoviral vector encoding the cytosine deaminase transgene (Ad-CMV-CD). In vitro, transduction with Ad-CMV-CD followed by exposure to 400 micro M 5-fluorocytosine resulted in complete elimination of clonogenic contaminating tumor cells without affecting the clonogenic potential of the human hematopoietic CD34(+) cells. Transplantation of nonobese diabetic/LtSz-scid/severe combined immunodeficient (NOD/SCID) mice with nonpurged contaminated grafts and purged contaminated grafts, allowed us to test the safety and efficacy of our procedure in two independent purging experiments. Hematopoietic engraftment kinetics as well as the quantity and quality of human engraftment were not affected by the purging therapy. Results showed a significant difference in survival between the nonpurged group (28%) and the purged group (100%; P = 0.012). Moreover, highly sensitive histological and molecular analyses confirmed the absence of tumor cells in the recipients of purged marrow. In contrast, metastatic tumors were detected in animals that received nonpurged grafts. We anticipate that this strategy will result in a safe and efficacious hematopoietic graft product for autologous transplantation for patients with multiple forms of epithelial cancers.